Aneurysmal Subarachnoid Hemorrhage (SAH) - Pipeline Review, Q2 2011

Global Markets Direct
April 30, 2011
34 Pages - SKU: GMD6354667
Aneurysmal Subarachnoid Hemorrhage (SAH) - Pipeline Review, Q2 2011

Summary

Global Markets Direct’s, 'Aneurysmal Subarachnoid Hemorrhage (SAH) - Pipeline Review, Q2 2011', provides an overview of the Aneurysmal Subarachnoid Hemorrhage (SAH) therapeutic pipeline. This report provides information on the therapeutic development for Aneurysmal Subarachnoid Hemorrhage (SAH), complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Aneurysmal Subarachnoid Hemorrhage (SAH). 'Aneurysmal Subarachnoid Hemorrhage (SAH) - Pipeline Review, Q2 2011' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope
  • A snapshot of the global therapeutic scenario for Aneurysmal Subarachnoid Hemorrhage (SAH).
  • A review of the Aneurysmal Subarachnoid Hemorrhage (SAH) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • Coverage of products based on various stages of development ranging from discovery till registration stages.
  • A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
  • Coverage of the Aneurysmal Subarachnoid Hemorrhage (SAH) pipeline on the basis of therapeutic class, route of administration and molecule type.
  • Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
  • Key discontinued pipeline projects.
  • Latest news and deals relating to the products.
Reasons to buy
  • Identify and understand important and diverse types of therapeutics under development for Aneurysmal Subarachnoid Hemorrhage (SAH).
  • Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
  • Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
  • Devise corrective measures for pipeline projects by understanding Aneurysmal Subarachnoid Hemorrhage (SAH) pipeline depth and focus of Aneurysmal Subarachnoid Hemorrhage (SAH) therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.



More CNS/Neurology reports by Global Markets Direct

General Anxiety Disorder - Pipeline Review, H2 2014 by Global Markets Direct
General Anxiety Disorder - Pipeline Review, H2 2014SummaryGlobal Markets Direct’s, ‘General Anxiety Disorder - Pipeline Review, H2 2014’, provides an overview of the General Anxiety ...
Cerebral Infarction (Brain Infarction) - Pipeline Review, H2 2014 by Global Markets Direct
Cerebral Infarction (Brain Infarction) - Pipeline Review, H2 2014SummaryGlobal Markets Direct’s, ‘Cerebral Infarction (Brain Infarction) - Pipeline Review, H2 2014’, provides an overview of the ...
Memory Impairment - Pipeline Review, H2 2014 by Global Markets Direct
Memory Impairment - Pipeline Review, H2 2014SummaryGlobal Markets Direct’s, ‘Memory Impairment - Pipeline Review, H2 2014’, provides an overview of the Memory Impairment’s therapeutic pipeline.This ...
Mild Cognitive Impairment - Pipeline Review, H2 2014 by Global Markets Direct
Mild Cognitive Impairment - Pipeline Review, H2 2014SummaryGlobal Markets Direct’s, ‘Mild Cognitive Impairment - Pipeline Review, H2 2014’, provides an overview of the Mild Cognitive ...
See all reports like this >>

 

SELECT A LICENSE

    Online Download  USD 500  
    Global Site License  USD 1,500  
 
US: 800.298.5699
Int'l: +1.240.747.3093
 

Share this report


    Other tasks

     
     
    Join Alert Me now!
    Receive bi-weekly email alerts on new market research

    Sign up today!